Daxor Corporation

06/04/2026

Today we’re featuring our Vice President of Grants and Contracts, Noa Kohl!

Noa is a trained cellular and molecular biologist with research experience at the Weizmann Institute of Science and Weill Cornell Medical School. She brings over a decade of experience in assisting life science organizations secure non-dilutive funding from U.S. federal agencies and private foundations.

In her 7 years on the team, Noa has developed a robust portfolio of grants and contracts to support the development and validation Daxor’s technologies.

06/02/2026

Daxor announces that the United States Patent and Trademark Office has issued U.S. Patent No. 12,635,917 B2, titled “Remote Blood Volume Monitor,” expanding the company’s diagnostic capabilities to enable continuous, remote tracking of status using .

This patent represents significant progress in personalized, remote patient care , , , and .

Full press release here: https://daxor.com/daxor-corporation-receives-u-s-patent-for-breakthrough-remote-blood-volume-monitor/

05/28/2026

As National Critical Care Awareness and Recognition Month comes to a close, proudly honors the extraordinary dedication of and doctors. In the , every second counts, and your unwavering commitment to patient care saves lives daily.

Society of Critical Care Medicine (SCCM)

05/20/2026

Today we’re featuring Daxor's Vice President of Development and Operations, Linda Cooper!

With over 35 years of expertise, Linda leads our Oak Ridge headquarters—the nerve center for all Daxor operations. By overseeing both manufacturing and R&D, she drives our next-generation product development to ensure the future of technology is rooted in precision and innovation.

05/13/2026

The JACC Journals published a Clinical Case Series that highlighted how 's blood volume analysis ( ) uncovered a hidden polycythemia subtype in nearly 20% of patients.

Our patented, U.S. Food and Drug Administration-cleared diagnostic was found to detect critical volume issues missed by standard blood tests that drive patient outcomes, including higher and blood clot risks and a high incidence of polycythemia, which poses additional clinical challenges for patients if untreated.

Learn more: https://www.jacc.org/doi/10.1016/j.jaccas.2024.103077


Banner Health

05/12/2026

Stop chasing the "Creatinine Bump"! 🛑

By the time serum creatinine rises, the injury has often already occurred. We are looking at a "rearview mirror" of renal health. 📈

With AKI-related mortality rising by over 150% in certain patient populations recently (CDC WONDER, 2025), reactive medicine isn't enough. 🆘

🔗Read more in this month’s BVA Brief: https://www.linkedin.com/pulse/stop-waiting-creatinine-bump-proactive-aki-prevention-c1kle/

04/30/2026

You’re ready to titrate GDMT. You’ve done everything right. But do you actually know your patient’s volume status? Without objective BVA data, you might be fighting a losing battle.

Get the full insights in our CMO's latest "In The Know" update. https://www.linkedin.com/pulse/guidelines-arent-problem-your-data-daxorcorporation-s9edf/?trackingId=zsWGDsNHT9%2BXh41S3KJXUg%3D%3D

04/28/2026

Daxor will exhibit its new Analyzer ( ™) at the MedAxiom CV Transforum Spring’26 Conference, a premier event for thought leaders and industry innovators to drive the future of cardiac care.

's participation underscores our team’s accelerating commercial integration and pivotal role in shaping the standard of care, positioning BVA™ at the forefront of a critical, high-growth cardiovascular market.

Full press release here: https://daxor.com/daxor-leverages-medaxiom-cv-transforum-spring26-to-accelerate-commercial-adoption-of-blood-volume-analysis/

Oak Ridge, TN – April 28, 2026 -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will exhibit

04/21/2026

Precision can change decisions, outcomes, and patient care. 's blood volume analysis ( ) technology supports diverse care settings and disease states where accurate volume measurement is critical.

BVA is useful from the ICU to outpatient care, delivering rapid, lab determined blood volume results in hospital and ambulatory environments. This supports clinicians to reduce diagnostic uncertainty and make confident treatment decisions.

As healthcare moves toward precision and value-based care, 's BVA is helping redefine how fluid management is measured, understood, and acted upon.

Learn more about Daxor’s game-changing BVA: https://daxor.com/



Important Safety Information: Rx only. For adults only. Contraindicated for pediatric, pregnant, or nursing patients. Informational purposes only; clinical interpretation by a qualified HCP required as individual outcomes vary.

04/16/2026

If you can’t measure it, can you truly treat it? 🔍

At , Dr. Jonathan Popham challenged the ICU status quo: traditional clinical scores often miss critical capillary leak.

The data:
✅ detected high albumin escape (20%/hr.) where clinical scores failed.
✅ Traditional metrics showed weak correlation with actual leakage.
✅ BVA remains the only tool to directly measure leakage in & .

Precision medicine requires objective data, not just estimates. 📊

🔗Read more in this month's BVA Brief: https://www.linkedin.com/pulse/unmet-need-identifying-hidden-leak-daxorcorporation-sp4ee/?trackingId=mGU2rHCrRtSYkSSJWBnP7A%3D%3D